董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bruno Baillavoine | 男 | Director | 69 | 58.39万美元 | 1.75 | 2022-12-27 |
| Gail Naughton | 女 | Director | 66 | 未披露 | 未持股 | 2022-12-27 |
| Geert R. Kersten | 男 | Director, Chief Executive and Financial Officer and Treasurer | 63 | 333.51万美元 | 217.74 | 2022-12-27 |
| Peter R. Young | 男 | Director | 77 | 58.89万美元 | 4.53 | 2022-12-27 |
| Robert Watson | 男 | Director | 66 | 58.39万美元 | 0.33 | 2022-12-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Geert R. Kersten | 男 | Director, Chief Executive and Financial Officer and Treasurer | 63 | 333.51万美元 | 217.74 | 2022-12-27 |
| Patricia B. Prichep | 女 | Senior Vice President of Operations and Corporate Secretary | 71 | 161.06万美元 | 27.25 | 2022-12-27 |
| Eyal Talor | 男 | Chief Scientific Officer | 66 | 153.96万美元 | 17.77 | 2022-12-27 |
| Daniel H. Zimmerman | 男 | Senior Vice President of Research, Cellular Immunology | 81 | 93.59万美元 | 12.43 | 2022-12-27 |
| John Cipriano | 男 | Senior Vice President of Regulatory Affairs | 80 | 91.06万美元 | 14.11 | 2022-12-27 |
董事简历
中英对照 | 中文 | 英文- Bruno Baillavoine
-
Bruno Baillavoine2015年6月加入CEL-SCI公司董事会。2010年以来，Baillavoine先生一直是Globomass Holdings Limited的合伙人，这是一家总部设在英格兰伦敦，从概念到最终运营可再生能源项目的开发商。自2012年起，Baillavoine先生一直担任Globomass Holdings的执行主席。Globomass Holdings在爱尔兰、保加利亚、克罗地亚、塞尔维亚都有子公司，并于最近收购了一家美国可再生能源公司20的股份。 1978年至1982年间，他是Ravenhead Ltd.的市场部经理，一家玻璃餐具的生产商和United Distillers Group（后来被Grand Metropolitan收购）。在此期间Baillavoine先生成为英国业务经理，在那里他恢复了United Distillers的市场份额和利润。1982年至1986年，Baillavoine先生是Prontaprint集团企业规划和集团营销总监，在那里他在4年内扩大了500个店铺。 1986至1988年，Baillavoine先生加入Grand Metropolitan Plc（现在的 Diageo Plc），一家富时100指数饮料、食品、酒店及休闲服务业集团，在特殊运营部门担任董事。在这个职位上，他为20000多个大蛋氨酸零售网点Grand Met‘s的故障排除部门开发计划。1988- 1991年，他是Nutri Systems （UK） Ltd.的董事总经理，这是一家美国专业监督减肥计划的子公司。 1991年至1995年，Baillavoine先生是BET Group plc（一家支持服务集团的跨国企业）的董事，并于1992年晋升为制造业务的董事总经理。在他任职期间BET的23亿欧元周转是FTSE 前100的公司最成功的周转之一。自1995年以来，Baillavoine先生曾在多个行业和地区担任多个首席执行官职位。 Baillavoine先生在欧洲和美国受教育（1972- 1976年在美国高中和University of Wisconsin Eau Claire）。
Bruno Baillavoine,joined CEL-SCI's board of directors in June 2015. Since 2017, Mr. Baillavoine has been the Director, Head of Pericles Group UK the subsidiary of the Paris-based leading French consulting firm Pericles Consulting Holdings SAS. Pericles is an expert in the fields of Banking, Finance, Asset Management and Insurance with over 350 institutional clients. He has also been an advisor to the Board of CSL Inc, Combatives Sports League, a US Mixed Martial Arts company since 2017 and was appointed to the Board in 2019. Between 2010-2016, Mr. Baillavoine was a partner of Globomass Holdings Limited, a London, England based developer of renewable energy projects from concept through final operations. From 2012 and 2016 Mr. Baillavoine was the Executive Chairman of Globomass Holdings. Globomass was acquired by CleanBay Inc. in 2016. Mr. Baillavoine remains a significant shareholder in CleanBay Inc. Between 1978 and 1982 he was the marketing manager of Ravenhead Ltd., a manufacturer of glass tableware, and part of United Distillers Group (later acquired by Grand Metropolitan). During this time Mr. Baillavoine became the UK Business Manager where he restored market share and profit for United Distillers. From 1982 to 1986 Mr. Baillavoine was Group Corporate Planning and Group Marketing Director for Prontaprint where he expanded the number of shops to 500 locations in four years. Mr. Baillavoine was with Grand Metropolitan Plc between 1986-1988 (now Diageo Plc), a FTSE 100 beverage, food, hotel and leisure company, as director in the Special Operations division. In this capacity, he developed plans for Grand Met's trouble-shooting division for over 20,000 Grand Met retail outlets. From 1988-1991 he was the Managing Director of Nutri Systems (UK) Ltd., a subsidiary of the US based provider of professionally supervised weight loss programs. Between 1991 and 1995, Mr. Baillavoine was Director of BET Group plc, a multinational business support services group, and in 1992, was promoted to the Managing Director for the manufacturing businesses. The 2.3 billion turnaround of BET during his tenure is one of the most successful turnarounds of a top 100 FTSE company. Since 1995, Mr. Baillavoine has held a number of CEO positions across a wide range of industries and geographical locations. Mr. Baillavoine has European and American educations (US high school and University of Wisconsin Eau Claire 1972-1976). - Bruno Baillavoine2015年6月加入CEL-SCI公司董事会。2010年以来，Baillavoine先生一直是Globomass Holdings Limited的合伙人，这是一家总部设在英格兰伦敦，从概念到最终运营可再生能源项目的开发商。自2012年起，Baillavoine先生一直担任Globomass Holdings的执行主席。Globomass Holdings在爱尔兰、保加利亚、克罗地亚、塞尔维亚都有子公司，并于最近收购了一家美国可再生能源公司20的股份。 1978年至1982年间，他是Ravenhead Ltd.的市场部经理，一家玻璃餐具的生产商和United Distillers Group（后来被Grand Metropolitan收购）。在此期间Baillavoine先生成为英国业务经理，在那里他恢复了United Distillers的市场份额和利润。1982年至1986年，Baillavoine先生是Prontaprint集团企业规划和集团营销总监，在那里他在4年内扩大了500个店铺。 1986至1988年，Baillavoine先生加入Grand Metropolitan Plc（现在的 Diageo Plc），一家富时100指数饮料、食品、酒店及休闲服务业集团，在特殊运营部门担任董事。在这个职位上，他为20000多个大蛋氨酸零售网点Grand Met‘s的故障排除部门开发计划。1988- 1991年，他是Nutri Systems （UK） Ltd.的董事总经理，这是一家美国专业监督减肥计划的子公司。 1991年至1995年，Baillavoine先生是BET Group plc（一家支持服务集团的跨国企业）的董事，并于1992年晋升为制造业务的董事总经理。在他任职期间BET的23亿欧元周转是FTSE 前100的公司最成功的周转之一。自1995年以来，Baillavoine先生曾在多个行业和地区担任多个首席执行官职位。 Baillavoine先生在欧洲和美国受教育（1972- 1976年在美国高中和University of Wisconsin Eau Claire）。
- Bruno Baillavoine,joined CEL-SCI's board of directors in June 2015. Since 2017, Mr. Baillavoine has been the Director, Head of Pericles Group UK the subsidiary of the Paris-based leading French consulting firm Pericles Consulting Holdings SAS. Pericles is an expert in the fields of Banking, Finance, Asset Management and Insurance with over 350 institutional clients. He has also been an advisor to the Board of CSL Inc, Combatives Sports League, a US Mixed Martial Arts company since 2017 and was appointed to the Board in 2019. Between 2010-2016, Mr. Baillavoine was a partner of Globomass Holdings Limited, a London, England based developer of renewable energy projects from concept through final operations. From 2012 and 2016 Mr. Baillavoine was the Executive Chairman of Globomass Holdings. Globomass was acquired by CleanBay Inc. in 2016. Mr. Baillavoine remains a significant shareholder in CleanBay Inc. Between 1978 and 1982 he was the marketing manager of Ravenhead Ltd., a manufacturer of glass tableware, and part of United Distillers Group (later acquired by Grand Metropolitan). During this time Mr. Baillavoine became the UK Business Manager where he restored market share and profit for United Distillers. From 1982 to 1986 Mr. Baillavoine was Group Corporate Planning and Group Marketing Director for Prontaprint where he expanded the number of shops to 500 locations in four years. Mr. Baillavoine was with Grand Metropolitan Plc between 1986-1988 (now Diageo Plc), a FTSE 100 beverage, food, hotel and leisure company, as director in the Special Operations division. In this capacity, he developed plans for Grand Met's trouble-shooting division for over 20,000 Grand Met retail outlets. From 1988-1991 he was the Managing Director of Nutri Systems (UK) Ltd., a subsidiary of the US based provider of professionally supervised weight loss programs. Between 1991 and 1995, Mr. Baillavoine was Director of BET Group plc, a multinational business support services group, and in 1992, was promoted to the Managing Director for the manufacturing businesses. The 2.3 billion turnaround of BET during his tenure is one of the most successful turnarounds of a top 100 FTSE company. Since 1995, Mr. Baillavoine has held a number of CEO positions across a wide range of industries and geographical locations. Mr. Baillavoine has European and American educations (US high school and University of Wisconsin Eau Claire 1972-1976).
- Gail Naughton
-
Gail Naughton博士自2022年8月起担任CEL-SCI主任。诺顿博士是再生医学领域超过35年的先驱。她是AdvancedTissueSciences的创始人，负责监督世界上第一个大规模的细胞产品制造工厂的设计和开发，与Smith & Nephew，Ltd.，Medtronic和InamedCorporation等公司建立了企业开发和营销合作伙伴关系，在从公开市场和企业合作中筹集超过3.5亿美元方面发挥了关键作用，并带来了四种基于人类细胞的产品从概念到FDA批准和上市。诺顿博士于2007年创立了Histogen公司，拥有超过125项美国和外国专利，并在该领域广泛发表。从2002年到2011年，诺顿博士一直担任圣地亚哥州立大学工商管理学院的院长，在那里，她帮助SDSU成为美国第一个建立生命科学博士/MBA学位的校区。2000年，诺顿博士获得了知识产权所有者协会颁发的第27届年度国家年度发明家奖，以表彰她在组织工程和再生医学领域的开创性工作。诺顿博士在纽约大学医学中心获得博士和硕士学位，并在加州大学洛杉矶分校获得MBA学位。她目前是Therapeutics医学博士的董事会成员，也是拉霍亚免疫学研究所的董事会主席。
Gail Naughton,Ph.D. has been a Director of CEL-SCI since August 2022. Dr. Naughton is a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch. Dr. Naughton founded Histogen Inc. in 2007 and holds more than 125 U.S. and foreign patents and has been extensively published in the field. Dr. Naughton served as Dean of the College of Business Administration at San Diego State University from 2002 until 2011, where she helped to make SDSU the first US campus to establish a Ph.D./MBA in life sciences. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering and regenerative medicine. Dr. Naughton received her Ph.D. and M.S. from NYU Medical Center, and an MBA from UCLA. She currently sits on the Board of directors of Therapeutics MD and is the Chair of the Board of the La Jolla Institute for Immunology. - Gail Naughton博士自2022年8月起担任CEL-SCI主任。诺顿博士是再生医学领域超过35年的先驱。她是AdvancedTissueSciences的创始人，负责监督世界上第一个大规模的细胞产品制造工厂的设计和开发，与Smith & Nephew，Ltd.，Medtronic和InamedCorporation等公司建立了企业开发和营销合作伙伴关系，在从公开市场和企业合作中筹集超过3.5亿美元方面发挥了关键作用，并带来了四种基于人类细胞的产品从概念到FDA批准和上市。诺顿博士于2007年创立了Histogen公司，拥有超过125项美国和外国专利，并在该领域广泛发表。从2002年到2011年，诺顿博士一直担任圣地亚哥州立大学工商管理学院的院长，在那里，她帮助SDSU成为美国第一个建立生命科学博士/MBA学位的校区。2000年，诺顿博士获得了知识产权所有者协会颁发的第27届年度国家年度发明家奖，以表彰她在组织工程和再生医学领域的开创性工作。诺顿博士在纽约大学医学中心获得博士和硕士学位，并在加州大学洛杉矶分校获得MBA学位。她目前是Therapeutics医学博士的董事会成员，也是拉霍亚免疫学研究所的董事会主席。
- Gail Naughton,Ph.D. has been a Director of CEL-SCI since August 2022. Dr. Naughton is a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch. Dr. Naughton founded Histogen Inc. in 2007 and holds more than 125 U.S. and foreign patents and has been extensively published in the field. Dr. Naughton served as Dean of the College of Business Administration at San Diego State University from 2002 until 2011, where she helped to make SDSU the first US campus to establish a Ph.D./MBA in life sciences. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering and regenerative medicine. Dr. Naughton received her Ph.D. and M.S. from NYU Medical Center, and an MBA from UCLA. She currently sits on the Board of directors of Therapeutics MD and is the Chair of the Board of the La Jolla Institute for Immunology.
- Geert R. Kersten
-
Geert R. Kersten自1995年 CEL-SCI公司担任领导职务。Mr. Kersten自1987年毕业的早些时候就在CEL-SCI工作。他在癌症领域首创免疫疗法，领先20年，成功领导CEL-SCI在生物产业攻克了很多难题。在加入CEL-SCI之前， Mr. Kersten在Finley & Kumble律师事务所和Source Capital公司工作，该公司是位于弗吉尼亚州麦克莱恩的投资银行。他是德国人，毕业于英格兰的米尔菲尔德中学，在美国完成学业。Mr. Kersten获得审计学士学位，乔治华盛顿大学获得工商管理硕士，华盛顿特区美国大学获得法学博士。
Geert R. Kersten,has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC. - Geert R. Kersten自1995年 CEL-SCI公司担任领导职务。Mr. Kersten自1987年毕业的早些时候就在CEL-SCI工作。他在癌症领域首创免疫疗法，领先20年，成功领导CEL-SCI在生物产业攻克了很多难题。在加入CEL-SCI之前， Mr. Kersten在Finley & Kumble律师事务所和Source Capital公司工作，该公司是位于弗吉尼亚州麦克莱恩的投资银行。他是德国人，毕业于英格兰的米尔菲尔德中学，在美国完成学业。Mr. Kersten获得审计学士学位，乔治华盛顿大学获得工商管理硕士，华盛顿特区美国大学获得法学博士。
- Geert R. Kersten,has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC.
- Peter R. Young
-
Peter R. Young博士，自2002年8月担任CEL-SCI主管。 Dr. Young在美国和加拿大担任制药领域的众多高级执行官。在过去的20多年里，他主要担任首席执行官，和首席金融官，拥有并购和出卖股权筹资的丰富经验。自2001年11月，Dr. Young担任Agnus Dei有限公司的总裁，是治疗癌症患者、多发性硬化、肝炎的免疫系统诊所组织的合作伙伴。自2003年1月Dr. Young担任SRL科技有限公司的专长和首席执行官，该公司是药物给药系统研发公司。在1998年至2001年，Dr. Young担任Adams实验室有限公司的首席金融官。Dr. Young在1969年英国布里斯托大学获得有机化学的博士学位，1966年布里斯托大学化学、数学、经济学硕士学位。
Peter R. Young,Ph.D. has been a Director of CEL-SCI since August 2002. Dr. Young has been a senior executive within the pharmaceutical industry in the United States and Canada for most of his career, originally in organizations that are now part of Sanofi S.A. Over the last 20 years he has primarily held positions of Chief Executive Officer or Chief Financial Officer and has extensive experience with acquisitions and equity financing. Since November 2001, Dr. Young has been the President of Agnus Dei, LLC, which has acted as a partner in an organization managing immune system clinics which treat patients with diseases such as cancer, multiple sclerosis and hepatitis. Dr. Young was also the President and Chief Executive Officer of SRL Technology, Inc., a company involved in the development of pharmaceutical drug delivery systems. Between 1998 and 2001, Dr. Young was the Chief Financial Officer of Adams Laboratories, Inc., the developer of Mucinex. Dr. Young received his Ph.D. in Organic Chemistry from the University of Bristol, England after obtaining his Bachelor's degree in Honors Chemistry, Mathematics and Economics. Subsequently, he qualified as a Fellow of the Chartered Institute of Management Accountants. - Peter R. Young博士，自2002年8月担任CEL-SCI主管。 Dr. Young在美国和加拿大担任制药领域的众多高级执行官。在过去的20多年里，他主要担任首席执行官，和首席金融官，拥有并购和出卖股权筹资的丰富经验。自2001年11月，Dr. Young担任Agnus Dei有限公司的总裁，是治疗癌症患者、多发性硬化、肝炎的免疫系统诊所组织的合作伙伴。自2003年1月Dr. Young担任SRL科技有限公司的专长和首席执行官，该公司是药物给药系统研发公司。在1998年至2001年，Dr. Young担任Adams实验室有限公司的首席金融官。Dr. Young在1969年英国布里斯托大学获得有机化学的博士学位，1966年布里斯托大学化学、数学、经济学硕士学位。
- Peter R. Young,Ph.D. has been a Director of CEL-SCI since August 2002. Dr. Young has been a senior executive within the pharmaceutical industry in the United States and Canada for most of his career, originally in organizations that are now part of Sanofi S.A. Over the last 20 years he has primarily held positions of Chief Executive Officer or Chief Financial Officer and has extensive experience with acquisitions and equity financing. Since November 2001, Dr. Young has been the President of Agnus Dei, LLC, which has acted as a partner in an organization managing immune system clinics which treat patients with diseases such as cancer, multiple sclerosis and hepatitis. Dr. Young was also the President and Chief Executive Officer of SRL Technology, Inc., a company involved in the development of pharmaceutical drug delivery systems. Between 1998 and 2001, Dr. Young was the Chief Financial Officer of Adams Laboratories, Inc., the developer of Mucinex. Dr. Young received his Ph.D. in Organic Chemistry from the University of Bristol, England after obtaining his Bachelor's degree in Honors Chemistry, Mathematics and Economics. Subsequently, he qualified as a Fellow of the Chartered Institute of Management Accountants.
- Robert Watson
-
Robert Watson，他拥有20年以上的经验，担任首席执行官兼大型营利科技企业的董事会董事。他一直担任一些公司的首席执行官，其中包括Mayne Nickless Computer Services、Data Sciences International （位于英国）、 Lend Lease Employer Systems公司。此外，他曾创立并开发一些信息技术产业的成功企业，其中包括ICON，这是澳大利亚公认的两倍增长最快的两个私人公司。他是SEEK Limited公司（在线就业分类企业，在澳大利亚证券交易所上市），以及一些私人公司的董事。他曾担任Cytopia Limited公司的执行主席（从2004年11月23日到2006年11月22日），随后担任Cytopia公司的非执行主席，直到2010年1月收购Cytopia YM公司。他也曾担任Cytopia公司的提名与薪酬委员会主席，以及审计和风险委员会的成员。
Robert Watson,has been a director of CEL-SCI since December 2017. Mr. Watson has been the President and CEO of Juvare, LLC (formerly Intermedix, Inc.) since July 2017. Immediately prior to joining Intermedix, now Juvare, he was the President and Chief Growth Officer of NantHealth, Inc. (Nasdaq: NH) from January 2015 to May 2017. Prior to NantHealth, he was President and CEO of Streamline Health, Inc. (Nasdaq: STRM) from January 2011 to January 2015. Mr. Watson has over 35 years of experience in the healthcare information technology industry as a CEO, board member and advisor to multiple healthcare information technology companies. He has participated in over 75 acquisitions, raised nearly $750 million in capital, completed three public offerings and successfully sold four companies. Mr. Watson holds a MBA from the Wharton School of Business at the University of Pennsylvania and a BA degree from Syracuse University. - Robert Watson，他拥有20年以上的经验，担任首席执行官兼大型营利科技企业的董事会董事。他一直担任一些公司的首席执行官，其中包括Mayne Nickless Computer Services、Data Sciences International （位于英国）、 Lend Lease Employer Systems公司。此外，他曾创立并开发一些信息技术产业的成功企业，其中包括ICON，这是澳大利亚公认的两倍增长最快的两个私人公司。他是SEEK Limited公司（在线就业分类企业，在澳大利亚证券交易所上市），以及一些私人公司的董事。他曾担任Cytopia Limited公司的执行主席（从2004年11月23日到2006年11月22日），随后担任Cytopia公司的非执行主席，直到2010年1月收购Cytopia YM公司。他也曾担任Cytopia公司的提名与薪酬委员会主席，以及审计和风险委员会的成员。
- Robert Watson,has been a director of CEL-SCI since December 2017. Mr. Watson has been the President and CEO of Juvare, LLC (formerly Intermedix, Inc.) since July 2017. Immediately prior to joining Intermedix, now Juvare, he was the President and Chief Growth Officer of NantHealth, Inc. (Nasdaq: NH) from January 2015 to May 2017. Prior to NantHealth, he was President and CEO of Streamline Health, Inc. (Nasdaq: STRM) from January 2011 to January 2015. Mr. Watson has over 35 years of experience in the healthcare information technology industry as a CEO, board member and advisor to multiple healthcare information technology companies. He has participated in over 75 acquisitions, raised nearly $750 million in capital, completed three public offerings and successfully sold four companies. Mr. Watson holds a MBA from the Wharton School of Business at the University of Pennsylvania and a BA degree from Syracuse University.
高管简历
中英对照 | 中文 | 英文- Geert R. Kersten
Geert R. Kersten自1995年 CEL-SCI公司担任领导职务。Mr. Kersten自1987年毕业的早些时候就在CEL-SCI工作。他在癌症领域首创免疫疗法，领先20年，成功领导CEL-SCI在生物产业攻克了很多难题。在加入CEL-SCI之前， Mr. Kersten在Finley & Kumble律师事务所和Source Capital公司工作，该公司是位于弗吉尼亚州麦克莱恩的投资银行。他是德国人，毕业于英格兰的米尔菲尔德中学，在美国完成学业。Mr. Kersten获得审计学士学位，乔治华盛顿大学获得工商管理硕士，华盛顿特区美国大学获得法学博士。
Geert R. Kersten,has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC.- Geert R. Kersten自1995年 CEL-SCI公司担任领导职务。Mr. Kersten自1987年毕业的早些时候就在CEL-SCI工作。他在癌症领域首创免疫疗法，领先20年，成功领导CEL-SCI在生物产业攻克了很多难题。在加入CEL-SCI之前， Mr. Kersten在Finley & Kumble律师事务所和Source Capital公司工作，该公司是位于弗吉尼亚州麦克莱恩的投资银行。他是德国人，毕业于英格兰的米尔菲尔德中学，在美国完成学业。Mr. Kersten获得审计学士学位，乔治华盛顿大学获得工商管理硕士，华盛顿特区美国大学获得法学博士。
- Geert R. Kersten,has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC.
- Patricia B. Prichep
Patricia B. Prichep于1992年加入CEL-SC，1994年3月担任CEL-SCI运营高级副总裁。在1992年12月至1994年3月，Ms. Prichep担任CEL-SCI运营主管。Ms. Prichep于2000年5月担任CEL-SCI的法团秘书。她负责CEL-SCI的所有日常营运事宜，包括：人力资源， 与CEL-SCI的独立注册公共会计公司联络财务报表。从1990年6月至1992年12月，Ms. Prichep担任质管经理和全国证券交易商协会产品、系统、支持竞标部门的管理。她负责内部审计和工作流程分析的操作。在1982年至1990年，Ms. Prichep担任Source Capital有限公司副总裁何运营经理。
Patricia B. Prichep,joined CEL-SCI in 1992 and has been CEL-SCI's Senior Vice President of Operations since March 1994. Between December 1992 and March 1994, Ms. Prichep was CEL-SCI's Director of Operations. Ms. Prichep became CEL-SCI's Corporate Secretary in May 2000. She is responsible for all day-to-day operations of CEL-SCI, including human resources and is the liaison with CEL-SCI's independent registered public accounting firm for financial reporting. From June 1990 to December 1992, Ms. Prichep was the Manager of Quality and Productivity for the NASD's Management, Systems and Support Department and was responsible for the internal auditing and work flow analysis of operations. Between 1982 and 1990, Ms. Prichep was Vice President and Operations Manager for Source Capital, Ltd. She handled all operations and compliance for Source Capital and was licensed as a securities broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut.- Patricia B. Prichep于1992年加入CEL-SC，1994年3月担任CEL-SCI运营高级副总裁。在1992年12月至1994年3月，Ms. Prichep担任CEL-SCI运营主管。Ms. Prichep于2000年5月担任CEL-SCI的法团秘书。她负责CEL-SCI的所有日常营运事宜，包括：人力资源， 与CEL-SCI的独立注册公共会计公司联络财务报表。从1990年6月至1992年12月，Ms. Prichep担任质管经理和全国证券交易商协会产品、系统、支持竞标部门的管理。她负责内部审计和工作流程分析的操作。在1982年至1990年，Ms. Prichep担任Source Capital有限公司副总裁何运营经理。
- Patricia B. Prichep,joined CEL-SCI in 1992 and has been CEL-SCI's Senior Vice President of Operations since March 1994. Between December 1992 and March 1994, Ms. Prichep was CEL-SCI's Director of Operations. Ms. Prichep became CEL-SCI's Corporate Secretary in May 2000. She is responsible for all day-to-day operations of CEL-SCI, including human resources and is the liaison with CEL-SCI's independent registered public accounting firm for financial reporting. From June 1990 to December 1992, Ms. Prichep was the Manager of Quality and Productivity for the NASD's Management, Systems and Support Department and was responsible for the internal auditing and work flow analysis of operations. Between 1982 and 1990, Ms. Prichep was Vice President and Operations Manager for Source Capital, Ltd. She handled all operations and compliance for Source Capital and was licensed as a securities broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut.
- Eyal Talor
Eyal Talor博士。1993年10月加入CEL-SCI。2009年10月，他被提升为首席科学官。在此晋升之前，他是研究和制造高级副总裁。他是一名临床免疫学家，在免疫治疗应用的临床研究和药物开发方面拥有超过27年的实践管理经验；生物制药行业的临床前至III期临床试验。他的专长包括生物制药研发和生物制品开发，GMP（良好生产规范）制造，质量控制测试以及GMP生产和测试设施的设计和建设。他曾担任临床实验室主任（由马里兰州认证），并在临床前和临床试验（I - III期）和GCP（良好临床实践）要求的设计方面拥有经验。他在FDA/GMP、USP和ICH指导方针下的生物测定开发、分析方法验证、原材料规格和QC（质量控制）测试开发的不同方面也拥有丰富的经验。他在IND和其他监管提交文件的准备方面拥有丰富的经验。他的科学专业领域包括免疫反应评估。他是超过25篇出版物的作者，并发表了一些关于临床免疫学的免疫调节的评论。在加入CEL-SCI之前，他曾担任CBL， Inc.的研发和临床开发总监，SRA Technologies, Inc.的首席科学家-项目总监和临床实验室总监。在此之前，他是The Johns Hopkins University， Medical Institutions的全职教员；公共卫生学院。他发明的技术已获得10项已颁发的专利，包括cell - sci Corporation e在癌症中的Multikine的物质组成和方法，以及两项平台肽技术，抗原定向t细胞凋亡（“Adapt”）和LEAPS，用于治疗自身免疫性疾病，哮喘，过敏，移植排斥和传染病。他还负责许多产品和工艺发明以及许多未决的美国和PCT专利申请。他在加拿大安大略省渥太华大学获得微生物学和免疫学博士学位，并在美国马里兰州巴尔的摩市约翰霍普金斯大学接受临床和细胞免疫学博士后培训。他在约翰霍普金斯大学医学机构担任助理教学职位。
Eyal Talor,Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 27 years of hands-on management of clinical research and drug development for immunotherapy application; pre-clinical to Phase III clinical trials, in the biopharmaceutical industry. His expertise includes biopharmaceutical R&D and Biologics product development, GMP (Good Manufacturing Practices) manufacture, Quality Control testing, and the design and building of GMP manufacturing and testing facilities. He served as Director of Clinical Laboratories (certified by the State of Maryland) and has experience in the design of pre-clinical and clinical trials (Phase I – III) and GCP (Good Clinical Practices) requirements. He also has broad experience in the different aspects of biological assay development, analytical methods validation, raw material specifications, and QC (Quality Control) tests development under FDA/GMP, USP, and ICH guidelines. He has extensive experience in the preparation of documentation for IND and other regulatory submissions. His scientific area of expertise encompasses immune response assessment. He is the author of over 25 publications and has published a number of reviews on immune regulations in relation to clinical immunology. Before coming to CEL-SCI, he was Director of R&D and Clinical Development at CBL, Inc., Principal Scientist - Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. Prior to that he was a full-time faculty member at The Johns Hopkins University, Medical Institutions; School of Public Health. He has invented technologies which are covered by ten issued patents on Multikine's composition of matter and method of Cel-Sci Corporation e in cancer and two platform Peptide technologies, Antigen Directed Apoptosis of T-cells ('Adapt') and LEAPS, for the treatment of autoimmune diseases, asthma, allergy, transplantation rejection and infectious diseases. He also is responsible for numerous product and process inventions as well as a number of pending US and PCT patent applications. He received his Ph.D. in Microbiology and Immunology from the University of Ottawa, Ottawa, Ontario, Canada, and had post-doctoral training in clinical and cellular immunology at The Johns Hopkins University, Baltimore, Maryland, USA. He holds an Associate teaching position at the Johns Hopkins University Medical Institutions.- Eyal Talor博士。1993年10月加入CEL-SCI。2009年10月，他被提升为首席科学官。在此晋升之前，他是研究和制造高级副总裁。他是一名临床免疫学家，在免疫治疗应用的临床研究和药物开发方面拥有超过27年的实践管理经验；生物制药行业的临床前至III期临床试验。他的专长包括生物制药研发和生物制品开发，GMP（良好生产规范）制造，质量控制测试以及GMP生产和测试设施的设计和建设。他曾担任临床实验室主任（由马里兰州认证），并在临床前和临床试验（I - III期）和GCP（良好临床实践）要求的设计方面拥有经验。他在FDA/GMP、USP和ICH指导方针下的生物测定开发、分析方法验证、原材料规格和QC（质量控制）测试开发的不同方面也拥有丰富的经验。他在IND和其他监管提交文件的准备方面拥有丰富的经验。他的科学专业领域包括免疫反应评估。他是超过25篇出版物的作者，并发表了一些关于临床免疫学的免疫调节的评论。在加入CEL-SCI之前，他曾担任CBL， Inc.的研发和临床开发总监，SRA Technologies, Inc.的首席科学家-项目总监和临床实验室总监。在此之前，他是The Johns Hopkins University， Medical Institutions的全职教员；公共卫生学院。他发明的技术已获得10项已颁发的专利，包括cell - sci Corporation e在癌症中的Multikine的物质组成和方法，以及两项平台肽技术，抗原定向t细胞凋亡（“Adapt”）和LEAPS，用于治疗自身免疫性疾病，哮喘，过敏，移植排斥和传染病。他还负责许多产品和工艺发明以及许多未决的美国和PCT专利申请。他在加拿大安大略省渥太华大学获得微生物学和免疫学博士学位，并在美国马里兰州巴尔的摩市约翰霍普金斯大学接受临床和细胞免疫学博士后培训。他在约翰霍普金斯大学医学机构担任助理教学职位。
- Eyal Talor,Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 27 years of hands-on management of clinical research and drug development for immunotherapy application; pre-clinical to Phase III clinical trials, in the biopharmaceutical industry. His expertise includes biopharmaceutical R&D and Biologics product development, GMP (Good Manufacturing Practices) manufacture, Quality Control testing, and the design and building of GMP manufacturing and testing facilities. He served as Director of Clinical Laboratories (certified by the State of Maryland) and has experience in the design of pre-clinical and clinical trials (Phase I – III) and GCP (Good Clinical Practices) requirements. He also has broad experience in the different aspects of biological assay development, analytical methods validation, raw material specifications, and QC (Quality Control) tests development under FDA/GMP, USP, and ICH guidelines. He has extensive experience in the preparation of documentation for IND and other regulatory submissions. His scientific area of expertise encompasses immune response assessment. He is the author of over 25 publications and has published a number of reviews on immune regulations in relation to clinical immunology. Before coming to CEL-SCI, he was Director of R&D and Clinical Development at CBL, Inc., Principal Scientist - Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. Prior to that he was a full-time faculty member at The Johns Hopkins University, Medical Institutions; School of Public Health. He has invented technologies which are covered by ten issued patents on Multikine's composition of matter and method of Cel-Sci Corporation e in cancer and two platform Peptide technologies, Antigen Directed Apoptosis of T-cells ('Adapt') and LEAPS, for the treatment of autoimmune diseases, asthma, allergy, transplantation rejection and infectious diseases. He also is responsible for numerous product and process inventions as well as a number of pending US and PCT patent applications. He received his Ph.D. in Microbiology and Immunology from the University of Ottawa, Ottawa, Ontario, Canada, and had post-doctoral training in clinical and cellular immunology at The Johns Hopkins University, Baltimore, Maryland, USA. He holds an Associate teaching position at the Johns Hopkins University Medical Institutions.
- Daniel H. Zimmerman
Daniel H. Zimmerman，医学博士，1996年至2008年12月、自2009年12月以来再度任CEL-SCI细胞免疫学高级副总裁。他于1996年一月加入CEL-SCI担任细胞免疫学研究副总裁。Dr. Zimmerman创立了CELL-MED有限公司，1987年至1995年担任总裁。1973年至1987年， Dr. Zimmerman在 Electronucleonics有限公司担任多个职务。他的职务包括：科学家、高级科学家、技术主管和项目经理。 Dr Zimmerman在1987年至1995年在蒙哥马利大学兼任教师职务。Dr. Zimmerman已经发明超过12个很多外国相似的美国科技专利。他是40多本免疫学与传染性疾科学读物的作者。他已获得由国家卫生研究所和美国国防部颁发的众多奖项。从1969年至1973年Dr. Zimmerman是国家卫生研究所的的高级职员。在之后的25年里，他继续为国家卫生研究所工作，担任客座研究员。 Dr. Zimmerman于1969年获得生物化学博士学位，1966年获得佛罗里达大学动物学硕士学位，1963年获得艾墨利与亨利学院生物学士学位。
Daniel H. Zimmerman,Ph.D. was CEL-SCI's Senior Vice President of Research, Cellular Immunology between 1996 and December 2008 and again since November 2009. He joined CEL-SCI in January 1996 as the Vice President of Research, Cellular Immunology. Dr. Zimmerman founded CELL-MED, Inc. and was its president from 1987-1995. From 1973-1987, Dr. Zimmerman served in various positions at Electronucleonics, Inc. His positions included: Scientist, Senior Scientist, Technical Director and Program Manager. Dr. Zimmerman held various teaching positions at Montgomery College between 1987 and 1995. Dr. Zimmerman has invented technologies which are covered by over a dozen US patents as well as many foreign equivalent patents. He is the author of over 50 scientific publications in the area of immunology and infectious diseases. He has been awarded numerous grants from National Institutes of Health, or NIH, and the Department of Defense, or DOD. From 1969-1973, Dr. Zimmerman was a Senior Staff Fellow at NIH. For the following 25 years, he continued on at NIH as a guest worker. Dr. Zimmerman received a Ph.D. in Biochemistry in 1969, and a Masters in Zoology in 1966 from the University of Florida as well as a B.S. in Biology from Emory and Henry College in 1963.- Daniel H. Zimmerman，医学博士，1996年至2008年12月、自2009年12月以来再度任CEL-SCI细胞免疫学高级副总裁。他于1996年一月加入CEL-SCI担任细胞免疫学研究副总裁。Dr. Zimmerman创立了CELL-MED有限公司，1987年至1995年担任总裁。1973年至1987年， Dr. Zimmerman在 Electronucleonics有限公司担任多个职务。他的职务包括：科学家、高级科学家、技术主管和项目经理。 Dr Zimmerman在1987年至1995年在蒙哥马利大学兼任教师职务。Dr. Zimmerman已经发明超过12个很多外国相似的美国科技专利。他是40多本免疫学与传染性疾科学读物的作者。他已获得由国家卫生研究所和美国国防部颁发的众多奖项。从1969年至1973年Dr. Zimmerman是国家卫生研究所的的高级职员。在之后的25年里，他继续为国家卫生研究所工作，担任客座研究员。 Dr. Zimmerman于1969年获得生物化学博士学位，1966年获得佛罗里达大学动物学硕士学位，1963年获得艾墨利与亨利学院生物学士学位。
- Daniel H. Zimmerman,Ph.D. was CEL-SCI's Senior Vice President of Research, Cellular Immunology between 1996 and December 2008 and again since November 2009. He joined CEL-SCI in January 1996 as the Vice President of Research, Cellular Immunology. Dr. Zimmerman founded CELL-MED, Inc. and was its president from 1987-1995. From 1973-1987, Dr. Zimmerman served in various positions at Electronucleonics, Inc. His positions included: Scientist, Senior Scientist, Technical Director and Program Manager. Dr. Zimmerman held various teaching positions at Montgomery College between 1987 and 1995. Dr. Zimmerman has invented technologies which are covered by over a dozen US patents as well as many foreign equivalent patents. He is the author of over 50 scientific publications in the area of immunology and infectious diseases. He has been awarded numerous grants from National Institutes of Health, or NIH, and the Department of Defense, or DOD. From 1969-1973, Dr. Zimmerman was a Senior Staff Fellow at NIH. For the following 25 years, he continued on at NIH as a guest worker. Dr. Zimmerman received a Ph.D. in Biochemistry in 1969, and a Masters in Zoology in 1966 from the University of Florida as well as a B.S. in Biology from Emory and Henry College in 1963.
- John Cipriano
John Cipriano于2004年3月至2008年12月、2009年10月再次担任 CEL-SCI法规事务高级副总裁。此外，他在美国食品药品监管局担任众多职务，包括，生物制剂新药临床实验部门、I生物研究办公室副局长、IND分部生物制品评价办公室、生物学办公室副主管。 Mr. Cipriano在波士顿麻省理工大学药学院获得药理学学士学位， 印第安纳州拉菲特西部普渡大学生物化学制药理科硕士学位。
John Cipriano,was CEL-SCI's Senior Vice President of Regulatory Affairs between March 2004 and December 2008 and again since October 2009.In addition, he held positions at the United States Food and Drug Administration (FDA) as Deputy Director, Division of Biologics Investigational New Drugs, Office of Biologics Research and Review and was the Deputy Director, IND Branch, Division of Biologics Evaluation, Office of Biologics. Mr. Cipriano completed his B.S. in Pharmacy from the Massachusetts College of Pharmacy in Boston, Massachusetts and his M.S. in Pharmaceutical Chemistry from Purdue University in West Lafayette, Indiana.- John Cipriano于2004年3月至2008年12月、2009年10月再次担任 CEL-SCI法规事务高级副总裁。此外，他在美国食品药品监管局担任众多职务，包括，生物制剂新药临床实验部门、I生物研究办公室副局长、IND分部生物制品评价办公室、生物学办公室副主管。 Mr. Cipriano在波士顿麻省理工大学药学院获得药理学学士学位， 印第安纳州拉菲特西部普渡大学生物化学制药理科硕士学位。
- John Cipriano,was CEL-SCI's Senior Vice President of Regulatory Affairs between March 2004 and December 2008 and again since October 2009.In addition, he held positions at the United States Food and Drug Administration (FDA) as Deputy Director, Division of Biologics Investigational New Drugs, Office of Biologics Research and Review and was the Deputy Director, IND Branch, Division of Biologics Evaluation, Office of Biologics. Mr. Cipriano completed his B.S. in Pharmacy from the Massachusetts College of Pharmacy in Boston, Massachusetts and his M.S. in Pharmaceutical Chemistry from Purdue University in West Lafayette, Indiana.